Eli Lilly and Company (NYSE:LLY) Stock Price Up 2.3% – Here’s Why

Shares of Eli Lilly and Company (NYSE:LLY) rose 2.3% during mid-day trading on Wednesday . The company traded as high as $961.14 and last traded at $952.2350. Approximately 2,565,046 shares were traded during mid-day trading, a decline of 19% from the average daily volume of 3,178,988 shares. The stock had previously closed at $931.09.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval for Lilly’s oral weight‑loss drug Foundayo has triggered bullish takeaways about revenue potential and re‑rated earnings outlooks. Great News for Eli Lilly Stock Investors!
• Positive Sentiment: An analyst price‑target lift and inclusion in “best buy” lists after the Foundayo approval supports upside expectations for sales and valuation. Price Target Raised Following FDA Approval for Fundayo
• Positive Sentiment: CEO Dave Ricks says Lilly is prepared to scale production of its new weight‑loss pill, reducing execution risk around supply constraints that could otherwise limit near‑term sales. LLY CEO Says Company Ready to Scale Production of Weight‑Loss Pill
• Positive Sentiment: Lilly extended its collaboration with AC Immune to advance next‑generation tau aggregation inhibitors, diversifying the pipeline into Alzheimer’s and supporting long‑term growth beyond obesity/diabetes. Eli Lilly Extends AC Immune Tau Pact
• Neutral Sentiment: Heightened investor attention and media coverage around Lilly (search/interest data) is driving volume and volatility but is mixed in directional impact. Investors Heavily Search Eli Lilly and Company
• Neutral Sentiment: Industry‑wide M&A and pipeline deals continue to reshape pharma dynamics; Lilly is an active participant but broader sector moves may be offsetting. Pharma, Biotech Giants Ramp Up M&A in Q1
• Negative Sentiment: Price competition intensified as Novo Nordisk launched a high‑dose Wegovy at a materially lower cash price (reported ~40% lower on some listings), which could pressure Foundayo adoption and pricing power. Novo Nordisk Unveils $399 Wegovy HD
• Negative Sentiment: Coverage notes the new Wegovy high‑dose listing is roughly $50 cheaper than Lilly’s competing branded option, highlighting near‑term market share and margin risk. A High Dose of Wegovy Will Cost $50 Less Than Zepbound
• Negative Sentiment: An analyst downgrade prompted short‑term selling and reflects concern about competitive pricing, side‑effect headlines and how much obesity upside is already priced in. LLY Trading Down on Analyst Downgrade
• Negative Sentiment: Some outlets flagged immediate investor worries after Foundayo approval — citing safety/side‑effect concerns and competitive intensity — which helps explain intra‑day volatility despite the approval. LLY Stock Dips Following FDA Approval of Foundayo

Analyst Ratings Changes

LLY has been the topic of a number of analyst reports. Wells Fargo & Company increased their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Bank of America increased their price target on Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the company a “buy” rating in a research report on Thursday, April 2nd. Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. BMO Capital Markets reiterated an “outperform” rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, Freedom Capital upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,222.22.

Eli Lilly and Company Trading Up 2.3%

The stock has a market capitalization of $899.69 billion, a PE ratio of 41.49, a PEG ratio of 1.09 and a beta of 0.51. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The business’s 50-day moving average is $988.75 and its two-hundred day moving average is $973.25.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same period in the previous year, the company earned $5.32 earnings per share. Eli Lilly and Company’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. 10Elms LLP lifted its position in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 10 shares during the last quarter. M.E. Allison & CO. Inc. raised its holdings in shares of Eli Lilly and Company by 0.7% in the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock valued at $1,587,000 after buying an additional 10 shares during the last quarter. Tanager Wealth Management LLP raised its holdings in shares of Eli Lilly and Company by 2.6% in the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock valued at $424,000 after buying an additional 10 shares during the last quarter. Morey & Quinn Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 1.5% in the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock valued at $710,000 after buying an additional 10 shares during the last quarter. Finally, Wealthspan Partners LLC raised its holdings in shares of Eli Lilly and Company by 0.5% in the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock valued at $2,268,000 after buying an additional 10 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.